clinical trial data
trials of lapatinib in combination with capecitabine
suspected adverse reactions
contact glaxosmithkline
fda
fda
www
fda.
gov/medwatch.
diarrhea
common adverse reaction
discontinuation of study medication
gastrointestinal side effects
diarrhea
nausea
vomiting
stomatitis
dyspepsia
hematologic side effects
laboratory abnormalities in hemoglobin
neutrophils
platelets
dermatologic side effects
palmar plantar erythrodysesthesia
called hand-foot syndrome
acral erythema
rash
dry skin
nail disorders
paronychia
hepatotoxicity
deaths
causality of the deaths
hepatotoxicity
days
several months after initiation of treatment
liver function tests
transaminases
bilirubin
alkaline phosphatase
initiation of treatment
weeks during treatment
changes in liver function
therapy with lapatinib
patients
lapatinib
lapatinib
patients with severe preexisting hepatic impairment
dose reduction
patients
severe hepatotoxicity
therapy
lapatinib
lapatinib
hepatic side effects
laboratory abnormalities in ast
total bilirubin
alt
potential cardiac toxicity with her
erbb
inhibitors
ventricular ejection fraction
lvef
clinical trials
eight-week intervals
lvef decreases
signs
symptoms of deterioration in left ventricular cardiac function
grade
nci ctcae
decrease in left ventricular cardiac ejection fraction
baseline
institution
lower limit of normal
patients
lapatinib/capecitabine combination treatment
experienced grade
grade lvef
adverse reactions
nci ctc
qt prolongation potential of lapatinib
part of an uncontrolled
open-label dose escalation study in advanced cancer patients
patients
daily doses of lapatinib
mg/day
mg/day
serial ecgs
day
day
effect of lapatinib on qt intervals
subjects
qtcf
corrected qt by the friedericia method
msec
increase in qtcf
automated machine-read evaluation of ecg
analysis of the data
relationship between lapatinib concentration
qtc interval
cardiovascular
side effects
decreases in left ventricular ejection fraction
qt prolongation
other side effects
mucosal inflammation
pain in the extremity
dyspnea
pain
insomnia
oncologic side effects
genotoxicity
impurity in the drug product
assays
patients
pulmonary symptoms
interstitial lung disease
pneumonitis
lapatinib
patients
pulmonary symptoms
interstitial lung disease/pneumonitis
grade
nci ctcae
respiratory side effects
been reported including
interstitial lung disease
pneumonitis in monotherapy
combination with other chemotherapies
hypersensitivity side effects
anaphylaxis
breathing
fainting
irregular heartbeat
severe diarrhea
tightness in the chest
unusual tiredness
weakness
stomach pain
tenderness
clay colored stools
dark urine
decreased appetite
fever
headache
itching
skin rash
loss of appetite
nausea and vomiting
swelling of the feet
lower legs
yellow eyes
skin
blistering
peeling
loosening of the skin
chest pain
chills
cough
diarrhea
difficulty with swallowing
dizziness
general feeling of discomfort
illness
hives
muscle pain
puffiness
swelling of the eyelids
eyes
face
lips
tongue
red skin lesions
purple center
red, irritated eyes
sore throat
sores
ulcers
white spots in the mouth
lips
thickening of bronchial secretions
acid
sour stomach
back pain
belching
cracked lips
diarrhea (mild)
dry skin
heartburn
indigestion
pain in the arms
legs
redness
swelling
painful skin
scaling of the skin on the hands
feet
sores
ulcers
white spots on the lips
tongue
inside of the mouth
stomach discomfort
pain
swelling
inflammation of the mouth
tingling of the hands
feet
trouble sleeping
loosening of the fingernails
redness
soreness around the fingernails